John Parkinson

Using the DRIP Score along with newer diagnostic technology may determine the course of antibiotics for certain patients with pneumonia more efficiently and efficaciously.

A member of the Infectious Diseases Society of America (IDSA) leadership feels there is some inroads being made in Congress for this antimicrobial resistance legislation.

After the Clinical and Laboratory Standards Institute (CLSI) revised their clinical breakpoints for susceptibility test results, a laboratory at a major medical center in a large midwest city evaluated enterobacterales as it relates to bloodstream infections (BSI) and piperacillin/tazobactam.

Late breaking data was reported utilizing the monoclonal antibody during the era of when Omicron variant was the predominant strain and demonstrated good outcomes and tolerability.

During a late breaking session at ID Week, an investigator presented data on the GSK vaccine that is in development.

Evidence on this has been conflicting and a poster presented at ID Week offers more insights on this significant topic.

After Helen Boucher, MD, gave the Maxwell Finland presentation she spoke of the continuing issues as well as the encouraging aspects that have institutions working on the problem.

There is an evolution of thinking about how this is treated and investigational therapies are looking to help these patients improve not only their medical conditions but give them back their quality-of-life.

Evidence demonstrates how these therapies are prescribed around patients’ races.

The Novavax booster dose administered in a small study induced more robust antibody responses and its safety profile was considered favorable.

A retrospective cohort study looked at the addition of utilizing a rapid test for gram-positive blood cultures and if time to diagnosis reduced vancomycin duration.

A Health-Related Quality of Life questionnaire designed to gather data on an investigational microbiota therapeutic demonstrated patients felt better about their conditions.

That country is trying to contain the virus to prevent further cases, as well as other African countries met to try to prevent an outbreak inside their own borders.

The Moderna vaccine can be administered to children as young as six years old and the Pfizer-BioNTech vaccine for kids as young as five years old.

The vaccine is meant to be administered during the third trimester of pregnancy to the expecting mother to prevent this respiratory disease in infants younger than 2 months of age.

The federal agency said it was looking at a multistate outbreak of the infection connected to Brie and Camembert soft cheese products manufactured by Old Europe Cheese.

The investigational therapy demonstrated time to first resolution of the five COVID-19 symptoms was significantly reduced in those treated with low dose of medication.

These vaccines target the wild strain as well as the Omicron BA.4/BA.5 variants.

This will include 3 trials to examine the therapy in different formulations in HIV studies.

The vaccine is available in adults 18 years and older.

The declaration not only puts the country on a list of countries circulating the viruses, but it also means polio continues to be transmitted in Rockland County, NY, and surrounding areas.

The brand’s specific meat product may contain E coli O157:H7.

WHO and CDC have laid out some ambitious goals for the treatment of hepatitis C, and HCV co-discoverer and vaccine developer Michael Houghton, PhD, offers some insights and commentary on whether he feels it is realistic to consider the eradication of this stubborn and subtle virus.

Nobel Prize Laureate Michael Houghton, PhD, discusses the arduous journey to find the virus and a subsequent investigational vaccine designed to prevent hepatitis C (HCV).

The federal agency's recommendation for both the Moderna and the Pfizer-BioNTech updated bivalent vaccines allows people to get the booster dose this fall.

Taking into account the first PrEP pill was FDA approved in 2012, a clinician reflects on its significance and where the shortcomings of education and utility of it needs to be fortified.

This Emergency Use Authorization for the Moderna and Pfizer-BioNTech vaccines brings them both one step closer for people to become eligible for these boosters.

A biotech company is utilizing this platform to rid people of the virus using a technology that differs from CRISPR-Cas9.

The Cambridge-MA., company accuses Pfizer and BioNTech of copying patented technology in the development of their COVID-19 vaccine.

From its results, the company plans to file a Biologics License Application (BLA) with the FDA.